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SObjective: We have analyzed short- and long-term variations of pulmonary function in locally advanced non–
small cell lung cancer after induction chemoradiotherapy.
Methods: Twenty-seven patients with stage IIIA (N2) non–small cell lung cancer underwent resection with rad-
ical intent after induction chemoradiotherapy in the period 2003 to 2006. Pulmonary function has been evaluated
by spirometry, diffusing capacity of the lung for carbon monoxide, and blood gas analysis before induction
chemoradiotherapy (T0), 4 weeks after induction chemoradiotherapy and before surgery (T1), and 1 (T2),
3 (T3), 6 (T4), and 12 months (T5) after surgery.
Results: A 22.80% decrease of diffusing capacity of the lung for carbon monoxide (P<.001) was observed at T1.
At T2 significant decreases in the following were present: vital capacity,20.50% (P<.001); forced vital capacity,
22.50% (P< .001); forced expiratory volume in 1 second,23.00% (P< .001); peak expiratory flow,29.0
(P<.001); forced expiratory flow 25% to 75%,13.7% (P¼ .005); and diffusing capacity of the lung for carbon
monoxide, 43.6% (P< .001). However, in the interval between T2 and T5, a progressive improvement of lung
function in most parameters was observed, but only diffusing capacity of the lung for carbon monoxide presented
a significant increase (P<.001). Within the same time gap (T2 to T5), subjects 65 years of age or younger showed
an increasing trend for vital capacity, forced expiratory volume in 1 second, total lung capacity, and residual
volume significantly different from that of elderly patients, in whom a decrease in these parameters is reported.
Conclusions: An impairment of respiratory function is evident in the immediate postoperative setting in patients
with non–small cell lung cancer receiving induction chemoradiotherapy. In the long-term period, a general recov-
ery in diffusing capacity of the lung for carbon monoxide was found, whereas an improvement of forced expira-
tory volume in 1 second, vital capacity, total lung capacity, and residual volume was detected in the younger
population only. (J Thorac Cardiovasc Surg 2010;139:1457-63)Concurrent radiochemotherapy is the standard of treatment in
stage III non–small cell lung cancer (NSCLC). In selected
cases a multidisciplinary approach, including induction che-
moradiotherapy (IT) and surgery, widened the chances of com-
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The Journal of Thoracic and CarThe fact that IT could increase perioperative morbidity
and mortality, mainly related to acute respiratory events, is
widely evidence based.7–9 Many studies have analyzed the
detrimental effects of radiotherapy (RT) and chemotherapy
(CT) on lung function in the short and long term. However,
to date and to our best knowledge, a comprehensive and se-
rial (ultra short, short, mid, long, and very long term) analy-
sis of pulmonary function in a homogeneous population of
patients with locally advanced non–small cell lung cancer
(NSCLC) who underwent an IT-plus-surgery protocol has
never been reported. We contend this despite recent reports
demonstrating the decrease in diffusing capacity of the lung
for carbon monoxide (DLCO) after IT radiotherapy–chemo-
therapy (RT-CT) as a predictor of postoperative pulmonary
morbidity.10
PATIENTS AND METHODS
Institutional review board approval has been obtained. The pulmonary
function data regarding a cohort of patients with locally advanced NSCLC
have been prospectively collected in the setting of an observational study
and evaluated in the period from January 2003 to January 2006. Consecu-
tive patients with NSCLC, pursuant a standard staging procedure anddiovascular Surgery c Volume 139, Number 6 1457
FIGURE 1. Consort diagram.
Abbreviations and Acronyms
CT ¼ chemotherapy
DLCO ¼ diffusing capacity of the lung for
carbon monoxide
FEF25%–75% ¼ forced expiratory flow 25%–75%
FEV1 ¼ forced expiratory volume in 1
second
FVC ¼ forced vital capacity
IT ¼ induction chemoradiotherapy
NSCLC ¼ non–small cell lung cancer
PaCO2 ¼ arterial blood pressure of carbon
dioxide
PaO2 ¼ arterial blood pressure of oxygen
PEF ¼ peak expiratory flow
RT ¼ radiotherapy
RT-CT ¼ radiotherapy–chemotherapy
RV ¼ residual volume
TLC ¼ total lung capacity
VC ¼ vital capacity
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Sa histologically proven (primitive tumor and homolateral mediastinal nodes)
diagnosis of locally advanced stage IIIa (N2), encountered the criteria fol-
lowed in our institution for the indication of a first step IT RT-CT eventually
followed by surgery (lobectomy only) on a comprehensive re-evaluation of
the tumor stage after IT (clinical restaging) (Figure 1).
Population Characteristics
From January 2003 to January 2006, we evaluated and treated 62 patients
with locally advanced NSCLC. Thirty-four patients showed a downstaging
or stable disease and underwent surgery. Of these, 4 patients were treated
with pneumonectomy and 3 patients continued treatments in other institu-
tions. Another 28 patients had a progression of disease or had complications
during IT treatment and were considered ineligible for surgery. The 27
patients who underwent lobectomy were considered in this study. The
mean age of the patients was 62.9  1.6 years and ranged from 40 to 80
years. Main population characteristics are described in Table 1.
Clinical Staging and Restaging: Pathologic Staging
The pretreatment evaluation included physical examination, blood anal-
ysis, electrocardiogram, fiberoptic bronchoscopy, computed tomographic
scan of the chest, abdomen, and brain, and radionuclide bone scan. The
diagnosis of NSCLC was obtained by pathologic and/or cytologic examina-
tion of material obtained via endobronchial biopsy or computed tomogra-
phy–guided fine needle aspiration. Mediastinal involvement was always
histologically (via mediastinoscopy) or cytologically (via computed tomog-
raphy–guided fine needle aspiration) confirmed.
A complete clinical restaging was performed 4 weeks after IT. Redo
mediastinoscopy was performed in selected cases.
IT Protocol
The treatment consisted of concurrent CT and RT.
Gemcitabine (350 mg/m2, or 300 mg/m2 for patients> 70 years) was
administered weekly as a 30-minute intravenous infusion at least 4 hours
before RT.
RT was administered with an individualized approach according to the
volume and location of the disease, with the requirement that 100% 1458 The Journal of Thoracic and Cardiovascular Sur5% isodose should encompass the entire target volume, with a maximum
dose for the spinal cord of 36 Gy. Gross tumor volume was the same as clin-
ical target volume plus target volume, and the planning volume was the clin-
ical target volume plus surrounding 1.5-cm margin. The elective nodal
irradiation was never administered. The prescription dose was 50.4 Gy,
given in daily single 1.8-Gy fractions or in a 1.2-Gy dose twice daily on
week days. A CT-based planning was performed in each case. Heterogene-
ity correction was routinely applied.
A photon beam (linear accelerator) with a 6- to 10-MV energy source
was used in all cases.
Pulmonary Function Evaluation
Pulmonary function tests were performed using the Spirometer System
(Biomedin, Padua, Italy). The DLCO was measured by the single breath
method and corrected with hemoglobin value. Blood gas analysis was
performed by sampling of radial artery blood.
The parameters we finally considered for this analysis are the absolute
value of vital capacity (VC), forced vital capacity (FVC), forced expiratory
volume at first second (FEV1), total lung capacity (TLC), residual volume
(RV), peak expiratory flow (PEF), forced expiratory flow 25%–75%
(FEF25–75), DLCO, arterial blood pressure of oxygen (PaO2), arterial blood
pressure of carbon dioxide (PaCO2), and pH.
All of the aforelisted parameters were measured before IT (time 0, T0),
4 weeks after IT and before surgery (time 1, T1), 1 month after surgery (time
2, T2), 3 months after surgery (time 3, T3), 6 months after surgery (time
4, T4), and 1 year after surgery (time 5, T5).
Further on, we stratified the cohort of patients according to age as
‘‘young’’ (<65 years old) and ‘‘elderly’’ (>65 years old) and according to
surgical intervention (all lobectomies) as ‘‘upper lobectomy’’ and ‘‘lower lo-
bectomy.’’ A cross comparison matching these criteria has then been realized.
Surgery
The criteria for surgery indication followed in our center are extensively
reported elsewhere.11 Put briefly, in locally advanced stage IIIA (N2)
NSCLC cases where an IT has been administered, we indicate surgery in
the so-called ‘‘responder’’ cases where a downstaging is obtained and in
all those cases where a progression of disease was not confirmed and where
a radical operation is reasonably foreseeable.
Surgery consisted of anatomic resection (lobectomies only were consid-
ered in this series) plus hilar and mediastinal systematic lymph node dissec-
tion,12 and it was performed 2 weeks (10–17 days) after clinical restaging
(thus, on an average, 6 weeks after the beginning of the IT) through a lateral
muscle-sparing thoracotomy. The resection was considered complete ifgery c June 2010
TABLE 1. Main population characteristics
Patients
No. %
Smoking habits
Yes 6 22.2
No 19 70.4
Ex 2 7.4
Gender
Male 20 74.1
Female 7 25.9
Comorbidity
No 19 70.4
Yes 8 29.6
COPD
No 18 66.7
Yes 9 33.3
Histology
Squamous 12 44.4
ADK 14 51.9
Adenosquamous 1 3.7
Surgery
RLL 4 14.8
LLL 4 14.8
ML 1 3.7
RUL 7 25.9
LUL 11 40.7
COPD, Chronic obstructive pulmonary disease; ADK, adenosine kinase; RLL, right
lower lobectomy; LLL, left lower lobectomy; ML, middle lobectomy; RUL, right upper
lobectomy; LUL, left upper lobectomy.
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tion and if the highest mediastinal resected node was free of tumor.
Follow-up
Patients were to be followed up at the first, third, sixth, and twelfth post-
operative months. Investigations included interim history, physical exami-
nation, laboratory tests, functional respiratory test, chest radiograph, and
oncologic follow-up.
Statistical Analysis
To compare the respiratory parameter means at different moments of the
follow-up time considering the nonindependence in the outcome, we
applied a log-normal random effect model,13 inasmuch as each individual
represented a cluster of allegedly correlated outcomes. This model takes
into account the within-subject correlation and provides accordingly suit-
able estimates of the standard errors of the regression coefficients. The fixed
effects estimated from this model correspond—for each respiratory param-
eter—to the relative difference between the mean at different steps of the
follow-up and the baseline. Gender, age, smoking habits, histology, comor-
bidity, and surgery have been considered as possible confounders and were
included in the models when they influenced the regression coefficients
estimate. c2 Statistic was applied to test the linear relationship between
the respiratory parameters and time. The analysis was performed with Stata
statistical software (Stata Corporation, College Station, Tex).14RESULTS
Surgery
The 30-day mortality was 2 (7.4%) of 27: 1 case of
myocardial infarction and 1 case of pulmonary embolism.The Journal of Thoracic and CarThe morbidity was 5 (18.5%) of 27. In 4 cases a respiratory
cause underlay the complication: 1 case of late bronchopleu-
ral fistula that caused the death of the patient 55 days after
surgery, 1 case of persistent air leak (8 days, spontaneous
closure), and 2 cases of acute respiratory failure (one 3
days after surgery, owing to lobar atelectasis in the residual
lung treated with bronchial aspiration, and one 2 days after
surgery, owing to lobar pneumonia that required 48 hours
of mechanical ventilation and prolonged [>7 days] antibi-
otic therapy). The remaining nonrespiratory complication
was a case of atrial fibrillation, medically treated. Age, gen-
der, IT response, and lung functionality were homogeneous
among the patients in whom a postoperative morbidity of
any type developed.
Three patients discontinued the planned follow-up ow-
ing to the appearance of distant metastases (1 at the level
of the bone, 2 at the level of the brain) and started pallia-
tive treatment. The remaining patients completed the
planned follow-up and thus the records included complete
respiratory data for the present analysis. All of the patients
who reached the twelfth month alive were free of evident
disease.
Respiratory Function
Table 2 and Figure 2 show the observed respiratory
parameter means at each follow-up time.
To measure the short-term effects of IT treatment and
surgery, we performed a multivariate regression analysis
for each functional parameter, comparing post-IT (T1) and
postoperative (T2) performances with baseline data (T0).
The results of this analysis are described in Table 3.
At time T1, only DLCO decline (22.80%; P<.001) was
significant and no particular worsening in each of the other
parameters at this time check point was observed.
At time T2, a significant decrease of VC (20.50%;
P< .001), FVC (22.50%; P< .001), FEV1 (23,00%;
P < .001), PEF (29,0; P < .001), FEF25–75 (13,7%;
P< .005), and DLCO (43.6%; P< .001) was present
with respect to T0.
The comparison of T1 to T2, which represents the effect
of acute perioperative changes, showed the same significant
differences as between T0 and T2 with the addition of TLC
(22.0%; P< .032).
The relationship between the respiratory parameters and
time after surgery (T2–T5) was explored by testing whether
the slope of the linear trend, estimated by the random effect
model, was significantly different from zero. Only DLCO
presented a significant increase from T2 to T5 (þ25.8%;
P ¼ .007).
We found that in younger subjects (aged  65 years), the
time trends after surgery for VC, FEV1, TLC, and RV were
significantly different from those of the elderly subjects
(aged>65 years) by testing the statistical interaction between
age and time of follow-up. In the younger group, VCdiovascular Surgery c Volume 139, Number 6 1459
TABLE 2. Respiratory parameter means at each time of the follow-up
Time of follow-up: mean (SE)
T0 T1 T2 T3 T4 T5
VC (L) 3.39 (0.16) 3.38 (0.15) 2.62 (0.16) 2.69 (0.16) 2.74 (0.15) 2.69 (0.16)
FVC (L) 3.29 (0.15) 3.26 (0.16) 2.49 (0.14) 2.55 (0.16) 2.60 (0.15) 2.55 (0.16)
FEV1 (L) 2.28 (0.14) 2.23 (0.15) 1.67 (0.13) 1.69 (0.12) 1.74 (0.14) 1.78 (0.15)
TLC (L) 5.25 (0.37) 5.49 (0.24) 4.26 (0.23) 4.34 (0.18) 4.39 (0.19) 4.28 (0.17)
RV (L) 2.17 (0.24) 2.15 (0.19) 1.62 (0.15) 1.56 (0.11) 1.60 (0.12) 1.54 (0.11)
PEF (L/s) 6.06 (0.48) 5.97 (0.46) 4.12 (0.39) 4.44 (0.30) 4.49 (0.40) 4.56 (0.43)
FEF 25-75 (L/s) 1.52 (0.19) 1.50 (0.18) 1.30 (0.23) 1.23 (0.22) 1.33 (0.26) 1.33 (0.22)
DLCO (mL $ mm Hg1 $ mm1) 15.42 (1.13) 13.58 (0.91) 8.94 (0.95) 9.29 (0.65) 11.91 (1.39) 12.05 (1.37)
PaO2 (mm Hg) 80.72 (2.07) 83.16 (1.85) 81.57 (2.52) 82.77 (2.33) 83.37 (3.36) 84.45 (2.81)
PaCO2 (mm Hg) 39.05 (0.87) 38.21 (1.02) 39.17 (1.01) 38.56 (0.42) 39.02 (0.74) 38.51 (0.86)
pH 7.45 (0.02) 7.46 (0.02) 7.44 (0.01) 7.43 (0.01) 7.43 (0.01) 7.43 (0.01)
VC, Vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; TLC, total lung capacity; RV, residual volume; PEF, peak expiratory flow; FEF 25–75,
forced expiratory flow25%–75%; DLCO, diffusing capacity of the lung for carbon monoxide; PaO2, arterial blood pressure of oxygen; PaCO2, arterial blood pressure of carbon
dioxide.
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.031) showed a progressive increment. Instead, in the elderly
patients, all the just-mentioned parameters did not show
significant variations (P ¼ not significant). The multivariate
models fitted for all parameters are reported in Table 3.
DISCUSSION
It has been clearly demonstrated that IT (different
paradigms) can increase morbidity and mortality after sur-
gery, mainly related to acute respiratory events.7–10 The
DLCO was found to be significantly and constantly
decreased in the IT (CT only, cisplatin plus gemcitabine
regimens) experiences recently reported by Leo,15 Maas,16
and their associates. An increase in perioperative morbidity
rate was reported as well. No reasoning was made with
respect to the understanding of such an event under these
specific conditions, where the need of a comprehensive anal-
ysis of prospectively gathered data remains unmet.
Where an association of CT and RT is considered within
an IT setting, the general idea is that a higher morbidity rate
is expected when a lung resection is performed owing to the
inclusion of the RT component. It is worth mentioning, to
allow the reader a careful and conservative interpretation
of this message, that this common belief is supported by
data that are at least heterogeneous. As well, we would
like to underline that the absence of a control group in this
observational analysis is due to the fact that we have
explored the pulmonary function of patients who undergone
CT-RT and surgery for locally advanced NSCLC. The only
possible comparison group would have been a surgical pop-
ulation without prior IT. This is not possible for two reasons:
first, because stage III NSCLC standard treatment is CT-RT;
second, because a surgical population (all lobectomies)
would be constituted by earlier stage cases and would lack
the main element under investigation, that is, the RT compo-
nent of the IT.1460 The Journal of Thoracic and Cardiovascular SurAt the moment of this writing, very few substantial data
are in fact available to cross match and discuss the effect of
induction RT-CT and surgery on pulmonary function. To
the best of our knowledge, none of those available is similar
to ours for number of serial time-trend checkpoints (1 pre-IT,
1 post-IT, and 3 postoperative), homogeneity (as regards
staging and surgical indication criteria and pulmonary func-
tion assessment), and completeness.
Abratt and Wilcox,17 in 1995, reported the effects of RT
on respiratory function and proved that the DLCO is con-
stantly decreased after irradiation (6 and 12 months after
treatment). Similarly, Borst and associates,18 in 2004,
reported that pulmonary function is significantly decreased
after RT. However, in both of these studies, the level of com-
plexity and heterogeneity is enhanced by the fact that the
patients, all with inoperable NSCLC, were treated with
high-dose exclusive RT (70 Gy) and never underwent
surgery.
The recently published experience from Takeda and asso-
ciates10 reported the results regarding the analysis of the
lung function before and after surgery in a cohort of cases
closer to ours (pulmonary resection after IT). It was demon-
strated that the DLCO is a clear and valid predictor of mor-
bidity (pulmonary) in the perioperative period. The authors
did not investigate pulmonary function beyond the surgical
step. Moreover, a certain degree of heterogeneity in the
population characteristics diminishes the value of the
conclusive figures. This was particularly true for the type
(extent) of resection and the type of IT (both cases where
CT alone and cases where RT-CT schemes were used had
been considered for the analysis; furthermore, in the CT
group, different chemotherapeutic regimens had been adop-
ted, these being known to have, among themselves, a differ-
ent impact on pulmonary function).
Still, in 2002, as additional information of side but useful
importance for this discussion, we have supported thegery c June 2010
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FIGURE 2. Respiratory parameter means at each time of the follow-up. VC, Vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in
1second; TLC, total lung capacity; DLCO, diffusing capacity of the lung for carbon monoxide; FEF 25%–75%, forced expiratory flow25%–75%; RV, residual
volume; PEF, peak expiratory flow.
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correlated with the extent of pulmonary resection to a greater
extent than to the IT treatment.6The Journal of Thoracic and CarAs well, it is to be considered that the evidence of the
decrease in pulmonary function is related to the dose and
the volume of irradiated parenchyma and, not lessdiovascular Surgery c Volume 139, Number 6 1461
TABLE 3. Multivariate regression analysis
Respiratory
parameters Time N
Mean
difference (%) 95% CI P value
VC T0 22 0.0
T1 27 1.2 6.0/3.8 .621
T2 16 20.5 25.2/15.6 <.001
FVC T0 22 0.0
T1 27 2.4 7.1/2.6 .340
T2 16 22.5 27.0/17.7 <.001
FEV1 T0 22 0.0
T1 27 3.5 7.4/0.5 .086
T2 16 23.0 26.7/19.0 <.001
TLC T0 19 0.0
T1 26 11.2 8.9/35.8 .296
T2 14 10.2 28.9/13.5 .368
RV T0 19 0.0
T1 26 1.5 15.5/14.8 .846
T2 14 15.2 29.4/1.7 .075
PEF T0 22 0.0
T1 27 3.0 11.5/6.2 .507
T2 16 29.0 36.5/20.7 <.001
FEF25–75 T0 22 0.0
T1 27 2.2 10.1/6.5 .612
T2 16 13.7 22.1/4.3 .005
DLCO T0 10 0.0
T1 15 22.8 32.3/12.0 <.001
T2 9 43.6 50.9/35.3 <.001
PaO2 T0 21 0.0
T1 27 3.2 0.8/7.3 .122
T2 16 2.2 2.6/7.2 .373
PaCO2 T0 21 0.0
T1 27 2.7 7.4/2.3 .285
T2 16 1.8 7.5/4.3 .562
pH T0 19 0.0
T1 27 0.1 0.5/0.3 .627
T2 15 0.2 0.7/0.2 .334
CI, Confidence interval; VC, vital capacity; FVC, forced vital capacity; FEV1, forced
expiratory volume in 1 second; TLC, total lung capacity; RV, residual volume; PEF,
peak expiratory flow; FEF25–75, forced expiratory flow 25%–75%; DLCO, diffusing
capacity of the lung for carbon monoxide; PaO2, arterial blood pressure of oxygen;
PaCO2, arterial blood pressure of carbon dioxide.
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Simportantly, to the quota of nonpathologically damaged
lung.19,21
Worth addressing herein is the relative effect the use of
conformational RT may have had on the reported outcome.
In fact, it appears intuitively clear that an irradiation of the
lung to a lesser (still accurate) extent and, therefore, the
resection of part of the lung damaged by irradiation could
indeed reduce the functional lung decrease. Over the im-
mediate postoperative period, this is more true in the
long term (when the residual healthy lung parenchyma is
recruited more and more extensively). This belief is sup-
ported by the fact that, in our experience, the functional de-
crease is more evident immediately after surgery instead of
soon after RT-CT. In this phase, in fact, the DCLO
(mainly) deterioration derives from subclinical damage to
the alveolocapillary membrane.10,15,22–24 The degree of1462 The Journal of Thoracic and Cardiovascular Surthis injury may be proportional to the extent of the
DLCO decline. It has been hypothesized to predict the
overall risk of respiratory postoperative morbidity.10,15
We could not confirm this double correlation (small popu-
lation and low morbidity rate).
Another issue that deserves some additional lines of
reasoning is the progressive improvement of lung function
with particular increase of the DLCO in all patients. When
the time gap from T2 and T5 is considered, the younger
subjects showed a significantly different pattern (VC, FEV1,
TLC, and RV) than the elderly ones, this being clearly
increased in the former group. The behavior of DLCO may
be correlated with a reduction of edema in the interstitial
space and with the degree of damage to the alveolocapillary
membrane. Despite the fact that we could not hypothesize
other pathophysiologic mechanisms, our data did not confirm
those (DLCO and FEV1 parameters’ behavior) reported in
previously published studies where these were constantly
and significantly decreased in the long term after RT-CT.17–20
Higher overall doses and different RT-CT schedules and
planning, along with the absence of the surgical step, could
easily justify this discrepancy (the irradiated parenchyma
stayed on site thus providing its ‘‘minus’’ to the global
pulmonary function).
The partial irreversibility of the obstructive damage in the
elderly population can support the evident difference
(‘‘none’’ versus ‘‘significant increase’’ of FEV1) with the
younger group. This is maintained despite the common
overarching improvement of flows induced by the parenchy-
mal resection in the midterm to long-term period. Moreover,
the increase of all pulmonary volumes (VC, TLC, RV) in the
younger patients could be related to a progressive easier
recovery of respiratory mechanics and muscular power
(with respect to the elderly) after surgery.
Finally, our data support the widely established evidence
that the predictive value of FEV1 and FVC assessed after IT
as indicators of the likelihood of respiratory postoperative
morbidity is inferior to that of DLCO, which is commonly
believed to be the most sensitive risk indicator in this set-
ting.15 As a matter of reference, a low preoperative DLCO
(<45%) is associated with an increase in postoperative mor-
bidity and mortality and predicts a poor quality of life25; fur-
thermore, a decrease of more than 20% in DLCO suggests
that a relevant, but of limited clinical value, degree of toxic
damage to the pulmonary parenchyma may have occurred.23
The moderate decline in DLCO preoperative levels (baseline
to T1,22.80%; P<.001) was in fact correlated with a very
low rate of pulmonary related postoperative complications.
Limitations and Recommendations
Functional evaluation before lung resection in patients
receiving neoadjuvant treatment remains controversial.
However, as similarly demonstrated in CT-only based regi-
mens, particular attention must be put on the DLCO levels.gery c June 2010
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SWe support the hypothesis that a decrease in DLCO (a
marker of alveolar–interstitial injury) could negatively affect
the risk of respiratory complications after surgery following
CT-RT.
We also believe that the FEV1 after IT is not a sensible
marker of postoperative complication (as demonstrated in
the T0–T1 period analysis of our study). Within the scopes
(and limits) of the reported setting, DLCO and FEV1 need
further investigation to gather sufficient proof and strength
to enter the clinical decision-making process as independent
parameters; in particular, for example, DLCO levels could
be possibly considered as cutoff criteria to stratify the preop-
erative risk in patients operated on after concurrent CT-RT
delivered at full therapeutic doses.
On the basis of these premises, we are currently evaluat-
ing, during the postoperative period (in the short and long
term), the value of DLCO levels as a reliable indicator of
lung function worsening or recovery. Furthermore, we are
investigating the relationship among the low DLCO levels
in the long-term post-RT complications and novel therapeu-
tic strategies including preoperative and postoperative
pulmonary rehabilitation.26,27
Finally, since they showed a slower recovery after sur-
gery, we recommend for elderly patients an intensive post-
operative respiratory rehabilitation program and follow-up
with particular attention to caloric support.CONCLUSION
The IT damages lung functionality (DLCO, flows, and
volumes) demonstrated by a significant decline of these
parameters. If directly matched within the setting of
a homogenous population, the degree of postoperative dam-
age is greater than that of post-IT damage.
In our series, the DLCO was constantly increased in the
entire population in the postoperative (up to 1 year) period.
The volumes and flows (FEV1, VC, TLC, and RV) demon-
strated a positive trend in the younger patients only. Our data
support the evidence that when the irradiated lung is then
excised, lung function injury is dependent on pulmonary
resection to a greater extent than on the IT, provided this
is administered along modern paradigms. Further investiga-
tion on the possible role of other treatment opportunities,
such as pulmonary rehabilitation scheduled along with the
IT plus surgery, is currently underway in our group, and
preliminary data will be available soon.
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